Oral Oncology
Volume 45, Issue 12 , Pages e211-e215 , December 2009

[18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer

  • Lukas B. Been

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • Address: Department of Surgical Oncology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, Groningen, The Netherlands. Tel.: +31 50 3616161; fax: +31 50 3614873.
    • ,
  • Harald J. Hoekstra

      Affiliations

    • Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9713 GZ Groningen, Groningen, The Netherlands. Tel.: +31 50 3612303; fax: +31 50 3614873.
    • ,
  • Albert J.H. Suurmeijer

      Affiliations

    • Department of Pathology and Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Pieter L. Jager

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Bernard F.A.M. van der Laan

      Affiliations

    • Department of Otorhinolaryngology – Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Philip H. Elsinga

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Received 4 June 2009 ,Revised 10 July 2009 ,Accepted 10 July 2009.

References 

  1. McGuirt WF, Greven KM, Keyes JW, et al. Positron emission tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngol. 1995;104(4 Pt 1):274–278
  2. Fu KK, Woodhouse RJ, Quivey JM, Phillips TL, Dedo HH. The significance of laryngeal edema following radiotherapy of carcinoma of the vocal cord. Cancer. 1982;49(4):655–658
  3. Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck. 2001;23(11):933–941
  4. Greven KM, Williams DW, Keyes JW, McGuirt WF, Watson NE, Case LD. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer?. Cancer J Sci Am. 1997;3(6):353–357
  5. Oe A, Kawabe J, Torii K, et al. Detection of local residual tumor after laryngeal cancer treatment using FDG-PET. Ann Nucl Med. 2007;21(1):9–13
  6. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg. 2004;130(12):1361–1367
  7. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23(10):1409–1415
  8. van der Putten L, Hoekstra OS, de Bree R, et al. 2-Deoxy-2[F-18]FDG-PET for detection of recurrent laryngeal carcinoma after radiotherapy: interobserver variability in reporting. Mol Imaging Biol. 2008;10(5):294–303
  9. Brouwer J, Hooft L, Hoekstra OS, et al. Systematic review: accuracy of imaging tests in the diagnosis of recurrent laryngeal carcinoma after radiotherapy. Head Neck. 2008;30(7):889–897
  10. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42(3):432–445
  11. de Boer JR, van der Laan BF, Pruim J, et al. Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas. Eur J Nucl Med Mol Imaging. 2002;29(9):1182–1187
  12. Wedman J, Pruim J, Langendijk JA, van der Laan BF. Visualization of small glottic laryngeal cancer using methyl-labeled (11)C-methionine positron emission tomography. Oral Oncol. 2009;
  13. Machulla HJ, Blochter A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Ch. 2000;243:843–846
  14. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27(2):235–238
  15. Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med. 1999;26(6):591–598
  16. Lowe VJ, Kim H, Boyd JH, Eisenbeis JF, Dunphy FR, Fletcher JW. Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-d-glucose PET imaging. Radiology. 1999;212(3):799–802
  17. Henze M, Mohammed A, Mier W, et al. Pretreatment evaluation of carcinomas of the hypopharynx and larynx with 18F-fluorodeoxyglucose, 123I-alpha-methyl-l-tyrosine and 99mTc-hexakis-2-methoxyisobutylisonitrile. Eur J Nucl Med Mol Imaging. 2002;29(3):324–330
  18. Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31(12):1659–1672
  19. Eriksson S, Kierdaszuk B, Munch-Petersen B, Oberg B, Johansson NG. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun. 1991;176(2):586–592
  20. Bardot V, Dutrillaux AM, Delattre JY, et al. Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. Br J Cancer. 1994;70(2):212–218
  21. Cole PD, Smith AK, Kamen BA. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother Pharmacol. 2002;50(2):111–116
  22. van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45(4):695–700
  23. Troost EG, Vogel WV, Merkx MA, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48(5):726–735
  24. Been LB, Elsinga PH, de Vries J, et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol. 2006;32(1):39–43
  25. Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129(2):393–401

PII: S1368-8375(09)00853-7

doi: 10.1016/j.oraloncology.2009.07.008

Oral Oncology
Volume 45, Issue 12 , Pages e211-e215 , December 2009

Article Tools

* Image Usage & Resolution